C-Jun Regulates Glucocorticoid-Mediated BIM Induction and Apoptosis in Leukemia Cells: An Alternative Target to Overcome Glucocorticoid-Resistance,
Authors: Heidari Nastaran , Marking Christine B , Hicks Mark A , Harada Hisashi 
Published: October 2019

Abstract 3486

Glucocorticoids (GC) are common components in many chemotherapeutic protocols for lymphoid/myeloid malignancies, including acute lymphoblastic leukemia (ALL). However, patients often develop resistance to GC on relapse. Resistance to GC in ALL can be associated with defects in apoptosis machinery not in the GC receptor. Thus, targeting downstream molecules may lead to the development of new therapeutic strategies.

GC-induced apoptosis is through the intrinsic mitochondria-dependent pathway. The BCL-2 family proteins are central regulatory proteins in this pathway. We and others have previously shown that BIM (BCL-2 Interacting Mediator of cell death), a pro-apoptotic BCL-2 family protein, is up-regulated by dexamethasone (Dex) treatment in ALL cells and plays an essential role in Dex-induced apoptosis (Lu et al., 2006). Furthermore, BIM is inactivated by extracellular signal-regulated kinase (ERK)-mediated phosphorylation by survival/growth factors (Harada et al., 2004). We therefore hypothesized that co-treatment with Dex and MEK/ERK inhibitors will promote apoptosis in ALL cells through BIM up-regulation and activation, resulting in cell death. Significantly, we have demonstrated that MEK inhibitors synergistically promote Dex lethality in a variety of ALL cell lines, in which BIM is a critical molecule in cell death (Rambal et al. 2009).

Since BIM is capable to interact with all anti-apoptotic BCL-2 family proteins (i.e. BCL-2, BCL-XL, MCL-1), we hypothesized that down-regulation/inactivation of the anti-apoptotic BCL-2 family proteins is also effective to enhance the activity of BIM. We found that down-regulation of anti-apoptotic BCL-2 family proteins, especially MCL-1, enhanced GC-induced cell death. We then targeted MCL-1 in ALL cells by using GX15-070 (obatoclax), a small molecule inhibitor for anti-apoptotic BCL-2 family proteins. Treatment with GX15-070 in both Dex-sensitive and -resistant ALL cells showed effective growth inhibition and cell death (Heidari et al. 2010). GX15-070 treatment in ALL could be an alternative regimen to overcome GC-resistance.

To further explore new treatments to overcome resistance to GC, it is important to elucidate entire signaling pathways for the activation of BIM in GC treatment. It has been indicated that Dex-induced BIM is regulated mainly by transcription, however the molecular mechanisms, including responsible transcription factors, of how Bim is induced are unclear. In this study, we examined the role of c-Jun in Dex-induced Bim transcriptional regulation in ALL cells. Dex treatment induced c-Jun mRNA and protein in parallel with BIM induction. BIM induction decreased in cells harboring dominant-negative c-Jun protein and increased in cells with overexpression of c-Jun. On the Bim promoter, c-Jun bound to and activated the AP-1 binding site at about −2.7kb from the transcription start site. Furthermore, pre-treatment with SB203580, a p38-MAPK inhibitor, decreased the amount of Dex-induced mRNAs and proteins of c-Jun and BIM, suggesting that p38-MAPK activation is upstream of c-Jun and BIM induction. Treatment with RU486, a GC receptor (GR) antagonist, blocked Dex-induced p38-MAPK phosphorylation, c-Jun and BIM induction, and apoptosis. In conclusion, we identified the critical signaling pathway for GC-induced apoptosis, i.e. GC–>GR–>p38-MAPK–>c-Jun–>BIM–>Apoptosis. Targeting this pathway may be an alternative approach to overcome GC-resistance in leukemia treatment.

Disclosures:

No relevant conflicts of interest to declare.